No Data
No Data
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
Express News | Shares of Weight Loss Stocks Are Trading Lower, Possibly on Continued Weakness Following Recent Weight Loss Data From Roche, Which Could Cause Competition Concerns for Companies in the Space
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Express News | Structure Therapeutics Shares Are Trading Lower Following Weight Loss Data From Competitor Roche
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
No Data